Facial anatomy applied to live models / Anatomia facial aplicada em modelos vivos

Introduction: Anatomy is one of the foundations in medicine, and choosing a practical and dynamic teaching method is essential for better retention of your learning. The objective is to use facial anatomy applied to live models as an innovative teaching strategy and to evaluate the experience of the learning experience of students assigned to the method. Method: The work analyzes the experience with body painting of 51 students from Instituto Boggio assigned this method (or instructed to use this method) during their classes. Different planes and anatomical structures were represented on live models' faces to simulate and teach the main injectable cosmetic procedures; syringes, needles, cannulas, and ultrasound gel stained with food inks were used. Overlapping latex layers were used for the anatomical study of the temple, middle third of the face, and nose, allowing the reproduction of fillers and biostimulators in these regions. The main muscle groups were represented for the discussion of high-precision botulinum toxin. After the entire demonstration, the students answered a questionnaire via "Google Forms" evaluating the methodology used. Results: According to the answers to the questionnaires, most students considered body painting an innovative methodology that contributed to learning anatomical content and satisfactorily illustrating the demonstrated cosmetic procedures. Conclusion: Practical learning through live models makes this new teaching method something innovative and unique that, in an enjoyable way, enables the study of anatomy and appropriately trains clinical skills.

Introdução: A anatomia é um dos principais alicerces no exercício da medicina e a escolha de um método de ensino prático e dinâmico é fundamental para melhor retenção do seu aprendizado. O objetivo é utilizar a anatomia facial aplicada em modelos vivos como estratégia inovadora de ensino e avaliar a experiência do processo de aprendizagem dos alunos submetidos ao método. Método: O trabalho analisa a experiência vivida com a pintura corporal por 51 alunos do Instituto Boggio submetidos ao método durante as aulas ministradas. Diferentes planos e estruturas anatômicas foram representados nas faces de modelos vivos. Para simulação e ensino dos principais procedimentos cosmiátricos injetáveis, seringas, agulhas, cânulas e gel de ultrassom corado com tintas alimentícias foram utilizados. Camadas de látex sobrepostas foram utilizadas para estudo anatômico da têmpora, terço médio da face e nariz, possibilitando a reprodução do uso de preenchedores e bioestimuladores nestas regiões. Os principais grupamentos musculares foram representados para discussão sobre toxina botulínica de alta precisão. Após toda a demonstração, os alunos responderam a um questionário via "Formulários Google" avaliando a metodologia utilizada. Resultados: De acordo com as respostas dos questionários, a maioria dos alunos considerou a pintura corporal como uma metodologia inovadora e que contribui no aprendizado do conteúdo anatômico, bem como ilustra satisfatoriamente os procedimentos cosmiátricos demonstrados. Conclusão: A aprendizagem prática por meio dos modelos vivos faz deste novo método de ensino algo inovador e único que, de maneira lúdica, possibilita o estudo da anatomia e o treinamento de habilidades clínicas adequadamente.

Treating the face of women with botulinum toxin type A: 7-year review / Tratamento da face de mulheres com toxina botulínica do tipo A: revisão de 7 anos

Introduction: Botulinum toxin type A (BTX-A) is the number one aesthetic procedure worldwide, and the difficulty in standardizing the aesthetic treatment of the face results in a broad range of treatment possibilities. The objective this study aimed to describe the author's experience treating facial wrinkles of women with BTX-A and suggest a standardized initial treatment method. Methods: A documentary retrospective review of all medical records from the main author's clinic from 2010 to 2017 in São Paulo, Brazil, was performed, searching for female patients who required the BTX-A aesthetic treatment to reduce facial wrinkles. The main author obtained, reviewed, and classified photographic data ("Carruthers Grading Scale for Forehead Lines"). Results: The BTX-A used in all patients was Botox® (Allergan Inc., Irvine, CA, USA). A total of 156 female treatments with BTX-A were identified. The average total units of BTX-A used for the referred treatment was 32.43U. The average period between treatments in the same patient was 8.73 months. All patients showed an improved "Grading Scale for Forehead Lines" post-treatment Conclusion: The review suggests a safe and effective technique is possible with even lower complication rates than found in the literature using fewer units, resulting in lower product costs. One should always try to minimize risks in aesthetic treatments.

Introdução: A aplicação de toxina botulínica do tipo A (BTX-A) é o procedimento estético mais realizado no mundo. Não há consenso sobre a forma ideal de realizar essa aplicação, que defina os locais de aplicação e a quantidade ideal necessária para o referido tratamento. O objetivo do estudo tem como objetivos descrever a experiência do autor no tratamento das rugas faciais em mulheres com BTX-A e sugerir uma padronização para o tratamento inicial. Método: Foi realizado um estudo documental retrospectivo de todos os prontuários médicos da clínica do autor principal, em São Paulo - SP, Brasil, desde 2010 até 2017, em busca dos dados de pacientes do sexo feminino que foram submetidas ao tratamento das rugas faciais com BTX-A, por razões estéticas. Os arquivos fotográficos foram obtidos, revisados e classificados pelo autor principal de acordo com a "Carruthers Grading Scale for Forehead Lines". Resultados: A BTX-A utilizada em todas as pacientes foi: Botox® (Allergan Inc., Irvine, CA, USA). Um total de 156 tratamentos com BTX-A foi encontrado. A média de unidade de toxina utilizada para o tratamento foi de 32,43U. O período médio de retorno para nova aplicação, na mesma paciente, foi de 8,73 meses. Todas as pacientes apresentaram melhora da classificação obtida através da "Grading Scale for Forehead Lines" após o tratamento. Conclusão: A revisão sugere que uma técnica efetiva e segura para o tratamento é possível, com menos unidades e menor taxa de complicações, quando comparada à literatura. Devemos sempre minimizar os riscos em tratamentos estéticos.

Comorbidity between chronic headache and depression treated with botulinum toxin: literature review / A comorbidade entre cefaleia crônica e depressão tratada com toxina botulínica: revisão da literatura

ABSTRACT BACKGROUND AND OBJECTIVES: It is estimated that up to 40% of patients with migraine have at least one episode of major depression during their lifetime. On the other hand, patients with depression are twice as likely to suffer from migraine when compared to the population without the mood disorder. The comorbidity of both conditions increases the frequency of pain crises and the individual's disability. A therapy that could act on the disorders, when simultaneous, would offer advantages through a broader and more effective action, such as botulinum toxin (BTX). Due to the lack of a clear definition on the subject, the objective of this study was to review how the concomitant treatment with BTX of the two morbidities behaves. CONTENTS: A review of articles in English, Portuguese, and Spanish indexed in Pubmed/Medline, LILACS and Scielo databases was carried out. Of the eight articles selected, most individuals were women aged 40 to 50 years. The sample size ranged from 30 to 715 subjects. The predominance was of prospective studies. All studies found a significant reduction in pain. Six studies found a significant decrease in depression. The frequency of adverse effects ranged from 4.1% to 30%, with eyelid ptosis and headache being the most frequent. CONCLUSION: BTX seems to be useful for the treatment of chronic headache and depression. There was a tendency to relate the improvement in depression with the decrease in pain. The specific action of the toxin in the treatment of depression was inconclusive. New studies, with high methodological rigor, as well as systematic reviews, should be carried out to reach a greater depth of comprehension of the subject and to determine the real efficacy of BTX in relieving concomitant headache and depression.

RESUMO JUSTIFICATIVA E OBJETIVOS: Estima-se que até 40% dos pacientes com migrânea apresentam, pelo menos, um episódio de depressão maior ao longo da vida. Por outro lado, pacientes com depressão apresentam duas vezes mais chance de ter migrânea quando comparados à população sem transtorno de humor. A comorbidade dos dois quadros aumenta a frequência das crises de dor e a incapacidade do indivíduo. Uma terapêutica que pudesse agir nos transtornos, quando simultâneos, ofereceria vantagens, por uma ação mais ampla e eficaz, a exemplo da toxina botulínica (TXB). Por faltar ainda uma clara definição sobre o tema, o objetivo deste estudo foi revisar como se comporta o tratamento concomitante das duas morbidades com a TXB. CONTEÚDO: Foi realizada revisão de artigos indexados nas bases de dados Pubmed/Medline, LILACS, Scielo nos idiomas inglês, português e espanhol. Dos oito artigos selecionados, a maioria dos indivíduos foram mulheres de 40 a 50 anos. O tamanho das amostras variou de 30 a 715 pacientes. A predominância foi de estudos prospectivos. Todos os estudos encontraram redução significativa da dor. Seis trabalhos encontraram diminuição significativa da depressão. A frequência dos efeitos adversos variou de 4,1% a 30%, sendo ptose palpebral e dor de cabeça os mais frequentes. CONCLUSÃO: A TXB parece ser útil para tratamento da cefaleia crônica e depressão. Houve uma tendência a relacionar a melhora da depressão com a diminuição da dor. A ação específica da toxina no tratamento da depressão foi inconclusiva. Novos estudos, com alto rigor metodológico, assim como revisões sistemáticas, deve ser realizados para alcançar maior aprofundamento do assunto, a fim de determinar a real eficácia da TXB no alívio da cefaleia e depressão concomitantes.

Evaluation of the botulinum toxin effects in the correction of gummy smile 32 weeks after application / Avaliação dos efeitos da toxina botulínica na correção do sorriso gengival 32 semanas pós-aplicação

INTRODUCTION: The use of botulinum toxin type A (BTX-A) to correct gummy smile has become popular in recent years. OBJECTIVE: To evaluate the effects of BTX-A application in the correction of gummy smile 2 and 32 weeks after application. METHODS: The sample comprised 35 patients (30 female, 5 male) at a mean age of 25.51 years (±5.59) with gummy smile due to muscular hyperfunction. In each patient, 2U of botulinum toxin was applied in the levator labii superioris alaeque nasi, 2 mm from the nasolabial fold. Photographs of spontaneous smiles were taken at 3 stages: before, 2 and 32 weeks after BTX application. Measurements of the gingival display were performed with the Radioface Studio 2 Software, and the calibration used the actual size of the right maxillary central incisor. Comparison of the three stages evaluated was performed with repeated measures ANOVA and Tukey tests. RESULTS: Gingival display decreased significantly 2 weeks after BTX-A application and increased after 32 weeks but did not return to the initial value. CONCLUSION: There was a significant improvement in gummy smile 2 weeks after botulinum toxin application, and a significant relapse in the gingival display after 32 weeks, however not returning to baseline values.

INTRODUÇÃO: A toxina botulínica tipo A (BTX-A) tem se tornado popular na correção do sorriso gengival nos últimos anos. OBJETIVO: Avaliar os efeitos da aplicação de BTX-A na correção do sorriso gengival 2 e 32 semanas após a aplicação. MÉTODOS: A amostra compreendeu 35 pacientes (30 mulheres, 5 homens) com uma idade inicial média 25,51 anos (±5,59) portadores de sorriso gengival devido à hiperfunção muscular. Em cada paciente foi aplicado 2U de BTX-A no músculo elevador superior da asa do nariz, 2 mm a partir da dobra nasolabial. Foram feitas fotografias dos sorrisos espontâneos dos pacientes em 3 fases: antes, 2 e 32 semanas após a aplicação de BTX-A. As medidas da exposição gengival foram feitas com o Software Radioface Studio 2, e a calibração utilizou o tamanho real do incisive central superior direito. A comparação das 3 fases foi feita com ANOVA de medidas repetidas e teste de Tukey. RESULTADOS: A exposição gengival diminuiu significantemente 2 semanas após a aplicação e aumentou novamente após 32 semanas, mas não retornando aos valores iniciais. CONCLUSÃO: Houve uma melhora significante no sorriso gengival 2 semanas após a aplicação de toxina Botulínica, e uma recidiva significante após 32 semanas, mas não retornando aos valores iniciais.

Recomendaciones de la Asociación Colombiana de Neurología para el uso de anticuerpos monoclonales antiCGRP en la profilaxis de migraña / Recommendations on the use of the antiCGRP monoclonal antibodies for migraine prophylaxis on behalf of the Colombian Association of Neurology

RESUMEN INTRODUCCIÓN: El desarrollo de anticuerpos monoclonales (mAbs) contra el péptido relacionado con el gen de la calcitonina (CGRP) ha determinado una nueva era terapéutica en la profilaxis de migraña, demostrando su efectividad en pacientes con migraña episódica (ME) y migraña crónica (MC), con respuesta desde pacientes naïve hasta refractarios a múltiples medicamentos. La disminución del 50% de los ataques de migraña al mes (DMM) durante los primeros 3 meses de uso es el desenlace aproximado en el 50% de los pacientes que reciben esta terapia. OBJETIVO: Este consenso de la Asociación Colombiana de Neurología (ACN) tiene el objetivo de guiar la selección y uso racional de los mAbs antiCGRP en pacientes con ME y MC. MATERIALES Y MÉTODOS: El comité de cefalea de la ACN mediante la aplicación de la metodología Delphi y discusiones en reuniones posteriores desarrolló un documento en formato de consenso soportado en literatura y recomendaciones de expertos. RESULTADOS: Se obtuvieron respuestas de 14 expertos en cefalea sobre moléculas utilizadas en profilaxis de migraña, analizando su aplicabilidad en situaciones clínicas frecuentes. DISCUSIÓN: Los mAbs antiCGRP han demostrado efectividad con adecuado soporte fisiopatológico, considerando que son moléculas de alto precio en una enfermedad de alta prevalencia, existe la necesidad de guíar la selección del paciente que mejor puede beneficiarse de su administración CONCLUSIONES: Los mAbs antiCGRP están recomendados en pacientes con ME y MC que presentan falla terapéutica a otras moléculas profilácticas.

ABSTRACT INTRODUCTION: The development of monoclonal antibodies (mAbs) against Calcitonin Gene Related Peptide (CGRP) has determined a new therapeutic era in migraine prophylaxis, demonstrating its effectiveness in patients with episodic migraine (EM) and chronic migraine (CM), obtaining a response in naive patients and in those who are refractory to multiple medications. A 50% decrease in migraine attacks per month during the first 3 months of use is the approximate outcome in 50% of patients receiving this therapy. OBJECTIVE: This consensus from the Colombian Association of Neurology (ACN) has the objective of serving as a guide for the rational use of antiCGRP mAbs in patients with EM and CM. METHODS AND MATERIALS: The headache committee through the application of the Delphi methodology and discussions in subsequent meetings, develops this consensus, supported in the published literature and expert recommendations. RESULTS: Fourteen answers from headache experts were received regarding the use of drugs for migraine prophylaxis, analyzing their applicability in frequent clinical situations. DISCUSSION: AntiCGRP mAbs have proved their effectiveness with adequate pathophysiological support, but with a high price in a highly prevalent disease, there is then a need to select the patient who best benefits from this therapy. CONCLUSIONS: AntiCGRP mAbs are recommended in patients with EM and CM that have previously failed to other prophylactic drugs.

A vacinação contra SARS-CoV-2 afeta o efeito imediato da toxina botulínica? Primeiras impressões / Does SARS-CoV-2 vaccination affect the immediate effect of botulinum toxin? First impressions

Introdução: A infecção por SARS-CoV-2 se espalhou rapidamente pelo mundo desde sua identificação no final de 2019. Globalmente, até abril de 2021, houve mais de 150 milhões de casos confirmados de Covid-19, incluindo mais de 3 milhões de mortes. Portanto, uma corrida foi prontamente iniciada para produzir uma vacina eficaz contra o novo vírus. A injeção de toxina botulínica continua sendo o principal procedimento cosmético não cirúrgico em todo o mundo, com alto índice de eficácia e satisfação do paciente. Objetivos: Este estudo tem como objetivo analisar a associação entre a vacina SARS-CoV-2 e a resposta imediata à toxina botulínica. Materiais e Métodos: Estudo observacional, retrospectivo e multicêntrico. Os dados foram coletados entre abril e junho de 2021, e revisão de prontuários de 71 pacientes de 27 a 76 anos que foram tratados com injeção de toxina botulínica. Resultados e Conclusão: Não houve mudanças significativas no desfecho imediato dos pacientes vacinados para Covid-19 e toxina botulínica, mas é de suma importância ressaltar que são necessários acompanhamento e mais estudos para definir se a vacina Covid-19 é capaz de alterar a duração do efeito e a eficiência da toxina botulínica.

Background: The SARS-CoV-2 infection has spread worldwide rapidly since its identification at the end of 2019. Globally, until April 2021, there have been more than 150 million confirmed cases of Covid-19, including over 3 million deaths. Therefore, a race was promptly started to produce an effective vaccine against the new virus. Botulinum toxin injection remains the leading non-surgical cosmetic procedure worldwide, with a high rate of efficacy and patient satisfaction. Aims: This study aims to analyze the association between the SARS-CoV-2 vaccine and the immediate botulinum toxin response. Materials and Methods: This was an observational, retrospective, and multicenter study. Data were collected between April and June 2021, and a medical record review of 71 patients from 27 to 76 years old treated with botulinum toxin injection. Results and Conclusion: There were no meaningful changes in the immediate outcome of patients vaccinated for Covid-19 and botulinum toxin. However, it is vital to underline that follow-up and further studies are needed to define whether the Covid-19 vaccine can alter the duration of effect and efficiency of the botulinum toxin.

Padrões de contração muscular e suas associações no terço superior da face: um estudo clínico e epidemiológico / Muscle contraction patterns and their associations in the upper third of the face: a clinical and epidemiological study

Introdução: o uso da toxina botulínica tornou-se um dos procedimentos cosméticos mais importantes realizados no mundo. Objetivo: identificar padrões de contração muscular da fronte, complexo glabelar e músculo orbicular dos olhos em pacientes do sul do Brasil, estabelecendo sua epidemiologia e possíveis associações entre eles. Métodos: foram incluídos 101 pacientes que buscaram tratamento com toxina botulínica para fronte, glabela e linhas perioculares entre 2012 e 2016. Análises foram feitas por meio de fotografias digitais tiradas durante consulta médica, antes da aplicação dos produtos. Os pacientes foram tratados com diferentes marcas de toxina botulínica, de acordo com suas preferências ou com as do médico. Resultados: os padrões de contração mais comuns foram frontal completo, glabelar em setas convergentes e periocular completo. Mulheres representaram 94,1% dos pacientes. A maioria tinha idade entre 31 e 50 anos, com média de 44,57 anos. Padrões mais frequentes em cada área individual foram mais frequentemente associados. Conclusões: o estudo mostra os principais padrões de contração muscular do terço superior da face em 101 pacientes, bem como suas características clínicas, e os compara com artigos publicados anteriormente. Estudos sobre padrões de contração muscular podem auxiliar no uso mais seguro e racional dos produtos disponíveis, evitando desperdícios e complicações.

Introduction: The use of botulinum toxin has become one the essential cosmetic procedures performed in the world. Objective: To identify patterns of muscle contraction of the forehead, glabellar complex, and orbicularis oculi muscle in patients from southern Brazil, establishing their epidemiology and possible associations between them. Methods: One hundred and one patients who sought treatment with botulinum toxin for the forehead, glabella, and periocular lines between 2012 and 2016 were included. Analyzes were made using digital photographs taken during a medical consultation before applying the products., The subjects received with different brands of botulinum toxin, according to the patients' or the doctors' preference Results: The most common contraction patterns were complete frontal, glabellar in converging arrows, and complete periocular. Women represented 94.1% of patients. Most patients were between 31 and 50 years old, with an average of 44.57 years. More frequent patterns in each area were more frequently associated. Conclusions: The study shows the main muscle contraction patterns of the upper third of the face in 101 patients, as well as their clinical characteristics, comparing them with previously published articles. Studies on muscle contraction patterns can assist in the safer and more rational use of the products available, avoiding waste and complications.

Effects of botulinum toxin A injection therapy with ultrasound-guided for benign masseter hypertrophy / 中华医学美学美容杂志

Objective:To evaluate the efficacy of botulinum toxin A injection therapy with ultrasound-guided for benign masseter hypertrophy.Methods:Twenty cases (40 sides) of masseter hypertrophy were injected with botulinum toxin A, among which 10 cases were taken as experimental group and the other 10 cases as control group. The experimental group had preoperative ultrasound examination to measure the thickness of masseter, and use ultrasound-guided precise injection during the operation, and then ultrasound recheck to measure the postoperative masseter thickness; The other 10 cases of control group adopt traditional 3-point injection method.Results:The masseter thickness of the two groups at different period of times after treatment was decreased ( P<0.001), the most obviously decrease happened 4-12 weeks after injection. The mean reduction was 26.8% at 4 weeks and 28.4% at 12 weeks after injection. Masseter muscle thickness recovered by 22% at 24 weeks and by 20% at 36 weeks. The average follow-up was 6.0±2.4 months with no serious complications occurred. In the control group, there was a partial masseter bulge in one case. The satisfactory rate of the patients in the experimental group was higher than that of the control group. Conclusions:Botulinum toxin A injection therapy with ultrasound-guided for benign masseter hypertrophy is an effective treatment, which is more accurate and effective than the traditional injection method.

Clinical effects of botulinum toxin A intradermal injection in treatment of erythematotelangiectatic rosacea / 中华医学美学美容杂志

Objective:To evaluate the efficacy and safety of intradermal injection of botulinum toxin A (BTX-A) in the treatment of erythematotelangiectatic rosacea.Methods:From January 2019 to December 2020, 30 patients with erythematotelangiectatic rosacea were treated in the Department of Dermatology at Xijing Hospital, Fourth Military Medical University. There were 26 females and 4 males, the age range from 23 to 42 years, with the average (30.9±5.7) years. Patients were randomly divided into two groups and given intradermal injection of botulinum toxin A. In detail, 0.25 U and 0.5 U was injected at each point in the low and high concentration group of BTX-A. The clinician erythema assessment (CEA) scores were recorded before treatment and at 2, 4, 8 and 12 weeks after treatment. The standard grading system scores for rosacea were recorded before treatment and at 12 weeks after treatment.Results:Both treatments could significantly reduce CEA scores, but the declined degree was more significant ( P<0.05), the onset time was shorter and the duration of efficacy was longer in the high concentration group. The scores of flushing, persistent erythema, burning sensation, stinging sensation and the total score of the standard grading system for rosacea after treatment in both two groups were significantly lower than those before treatment (high concentration group: t=5.00, 5.93, 4.10, 2.74, 12.37; low concentration group: t=6.17, 4.12, 2.87, 2.81, 7.88; P<0.05), and the improvement in high concentration group was significantly more than that in low concentration group ( t=2.02, 2.31, 2.15, 2.56, P<0.05). There was no significant difference in the overall effective rate between the two treatments ( P>0.05). Conclusions:Intradermal injection of BTX-A is safe and effective in the treatment of rosacea. Compared with the low concentration group, the efficacy is better, the onset time is shorter and the duration of efficacy is longer in the high concentration group.

Embelezamento facial com injetáveis e principais diferenças entre os gêneros / Facial beautification with fillers and main differences between genders

A percepção da beleza é ainda algo pouco compreendida, apesar de francamente notável. Pessoas consideradas belas notadamente tem melhor autoestima e um melhor desempenho em suas relações interpessoais. A procura por tratamentos cosmiátricos está em franca ascensão e o crescimento entre os homens é ainda maior. A perfeita compreensão das diferenças entre os atributos masculinizantes e feminilizantes em uma face deve ser encorajado, a fim de obter melhores resultados estéticos e a prevenção de estigmas de tratamento. Nesta revisão, será abordada cada região facial, pormenorizando os padrões de beleza de cada gênero, norteando os detalhes do tratamento.

The beauty perception is still poorly understood, though downright remarkable. People considered beautiful notably have better self-esteem and perform better in their interpersonal relationships. Demand for cosmetic treatments is on the rise and growth among men is even higher. Perfect understanding of the differences between masculinizing and feminizing attributes on a face should be encouraged in order to achieve better aesthetic results and the prevention of treatment stigmas. This review will cover each facial region, detailing the beauty standards of each gender, guiding the details of treatment.

Toxina botulínica A e repercussões na capacidade para andar de indivíduos pós acidente vascular cerebral: revisão sistemática / Botulinum toxin A and repercussions on the ability to walk in individuals after a stroke: systematic review

A indicação da toxina botulínica do tipo A (TBA) para indivíduos com história de acidente vascular cerebral (AVC) é uma prática clínica comum para redução da espasticidade. Objetivo: Investigar se a ação da TBA sem associação com outras intervenções impacta na capacidade da atividade de andar nos indivíduos pós-AVC. Método: Revisão sistemática com estudos provenientes da Cochrane Central Register of Controlled Trials, MEDLINE, SciELO, PEDro e LILACS, em inglês e português, entre 2010 a 2020. Foram incluídos ensaios clínicos controlados, com participantes pós AVC submetidos a aplicação de TBA em idades entre 18 a 50 anos de ambos os sexos. A seleção dos artigos foi realizada por dois avaliadores, com extração dos dados e avaliação de qualidade da evidência pela PEDro, segundo critérios de inclusão e exclusão pré-estabelecidos. Resultados: Dos 183 artigos, quatro permaneceram para análise final. A aplicação da TBA em indivíduos pós AVC ocorreu em sua maioria em flexores plantares e os achados relacionados com a atividade andar foram o aumento da passada, da velocidade da marcha, de distâncias percorridas ao caminhar e redução do tempo de execução de ações, como subir e descer degraus. Conclusão: A TBA proporciona melhora da capacidade para andar em indivíduos pós AVC e o conhecimento dos seus benefícios pós aplicação é essencial para informar aos pacientes da importância de aproveitar este momento, para modificar comportamentos que acentuam os padrões de compensação, que tanto corroboram para o retorno de limitações de atividades e não devido ao término da ação da TBA.

The indication of botulinum toxin type A (BoNTA) for individuals with a history of stroke is a common clinical practice for reducing spasticity. Objective: To investigate whether the action of TBA without association with other interventions impacts on the ability of walking activity in post-stroke individuals. Method: A systematic review with studies from the Cochrane Central Register of Controlled Trials, MEDLINE, SciELO, PEDro, and LILACS databases, in English and Portuguese, between 2010 and 2020. Controlled clinical trials were included, with post-stroke participants aged between 18 and 50, of both sexes, submitted themselves to the application of BoNTA. The selection of the articles was carried out by two evaluators, with data extraction and quality evaluation of the evidence by PEDro, according to pre-established inclusion and exclusion criteria. Results: Of the 183 articles, four remained for final analysis. The application of TBA in post-stroke individuals occurred mostly in plantar flexors and the findings related to walking activity were increased stride, gait speed, distances covered when walking and reduced time to perform actions, such as climbing and go down steps. Conclusion: TBA improves the ability to walk in post-stroke individuals and knowledge of its benefits after application is essential to inform patients of the importance of taking advantage of this moment,to modify behaviors that accentuate the compensation patterns, which so much corroborate for the return of activity limitations and not due to the termination of the TBA action.

Uso da toxina botulínica na hidradenite supurativa / Use of botulinum toxin in hidradenitis suppurativa

Introdução: hidradenite supurativa (HS) é uma condição inflamatória, crônica, recorrente e debilitante. Há uma falta de consenso sobre o seu tratamento. Objetivo: foi realizada revisão da literatura nacional e internacional, buscando-se artigos que abordassem o uso da toxina botulínica na HS, além de descrever as doses e técnicas utilizadas. Métodos: foi realizada busca bibliográfica nas bases LILACS, Medline e SciELO. Resultados: considera-se que a toxina botulínica pode ser eficaz em pacientes com HS, principalmente se houver hiperidrose concomitante e quando as terapias tradicionais falham. Oferece a possibilidade de realizar um tratamento com efeitos colaterais mínimos, repetíveis ao longo do tempo sem perda de eficácia, além de diminuir a dor. Conclusões: é provável que os pacientes precisem de mais de um tratamento com o tempo, pois as lesões tendem a se repetir após uma média de seis a 10 meses. Utiliza-se a técnica padrão para hiperidrose. Mais pesquisas são necessárias para entender o seu papel no gerenciamento da HS, incluindo dosagem e frequência ideais de administração.

Introduction: Hidradenitis suppurativa (HS) is an inflamatory, chronic, recurrent, and debilitating condition. There is a lack of consensus about its treatment. Objective: We conducted a review of the national and international literature, searching for articles that addressed the use of botulinum toxin in HS, in addition to describing the doses and techniques used. Methods: A bibliographic search was performed in LILACS, Medline, and SciELO. Results: Botulinum toxin can be an effective therapy in patients with HS, especially in cases of concomitant hyperhidrosis and traditional therapies fail. It offers the possibility of conducting treatment with minimal adverse events, reproducible over time without loss of effectiveness, in addition to reducing pain. Conclusions: Patients will likely need more than one treatment over time, as the lesions tend to recur after 6 to 10 months. The technique used has been the standard for hyperhidrosis. Further research is needed to understand its role in the management of HS, including the ideal dosage and frequency of administration

Desenvolvimento de alopecia fibrosante frontal em duas pacientes usuárias de toxina botulínica: relação ou coincidência? / Frontal fibrosing alopecia development in two patients after botulinum toxin applications: relationship or coincidence?

A alopecia frontal fibrosante é uma alopecia cicatricial linfocítica primária de difícil controle, com infiltrado liquenoide perifolicular marcando sua histologia. Desde a sua descrição em 1994 por Kossard houve um aumento de casos descritos pelo mundo. Este artigo relata dois casos em que foram realizadas biópsias incisionais com cortes longitudinais e transversais nas áreas que apresentaram maior atividade da doença e revisa alguns aspectos dessa dermatose, além de abordar a suspeita de uma possível relação com a aplicação de toxina botulínica - questão já aventada por outros autores, porém sem estabelecimento de confirmação.

Frontal fibrous alopecia is a primary lymphocytic scarring alopecia that is difficult to control, with a perifollicular lichenoid infiltrate marking its histology. Since its description in 1994 by Kossard, there has been an increase in cases reported worldwide. This article reports two cases that underwent incisional biopsies with longitudinal and transverse sections in areas presenting higher disease activity and reviews some aspects of this dermatosis. It also addresses the suspicion of a possible relationship with the application of botulinum toxin ­ a question already raised by other authors but with no established confirmation.

Effect of botulinum toxin type a in congenital muscular torticollis / 中华医学美学美容杂志

Objective:To discuss the clinical results of treatment for congenital muscular torticollis with different injection points of botulinum toxin type A and traditional conservative method, and to expound the safety and effectiveness of this way.Methods:From January 2018 to December 2018, 60 cases aged from one month to six months with congenital muscular torticollis who visited the outpatient clinic of plastic surgery in Children＇s Hospital of Quanzhou, a teaching hospital of FuJian Medical University, and there were 38 males and 22 females. The treatment groups were divided into two groups according to random number method that were treated with botulinum toxin type A: the single point group was given one point injection, and the three-point group was injected with three points, while the control group was treated with traditional conservative treatment (mainly manual stretching exercises). The number of cases in each group was 20.Results:The differences of muscle thickness and muscle length were repeatedly measured at different time points in the same group and variance analysis conducted. The results showed that there were statistical significances among the two indicators at different time points in each group ( P<0.05). Least significant difference (LSD) was further adopted for pairwise comparison between indicators at different time points in each group and the differences were statistically significant ( P<0.05). In the comparison of treatment effect of different groups after twelve months follow-up, the cure rate was 85% (17 cases) in the single point group, 95 % (19 cases) in the three-point group, and 80 % (16 cases) in the control group, there was no significant difference among three groups ( P>0.05). Conclusions:Local injection of botulinum toxin type A is a safe and effective treatment option for congenital muscular torticollis, which can achieve the same clinical effect as traditional conservative treatment.

Effect of botulinum toxin A on fat breastaugmentation: a preliminary randomized controlled clinical study / 中华医学美学美容杂志

Objective:To explore whether botulinum toxin A (BTX-A) can improve the retention rate of fat transplantation in fat breast augmentation.Methods:Each patient was divided into control side and experimental side according to the random number table in 14 patients studied. The experimental group received autologous fat and BTX-A combined transplantation on both sides of the breast, while the control side only received autologous fat transplantation. The fat was added with the same volume of normal saline as BTX-A in the control group. All patients were followed up and the effects of BTX-A were evaluated objectively via the comparison of the remained bilateral fat graft volumes that were obtained through a digital three-dimensional reconstructions technique. Moreover, the improvement of each breast appearance and complication were assessed by the physician and patients who were blinded to the recipient treatment assignment.Results:The outcome of the fat breast augmentation was evident for both groups at the follow-up with no evidence of fat embolism, vascular/nervous injury, infection and prolonged bruising. In one of the 14 patients (control group), fat liquefaction necrosis occurred in one side of the breast; after active treatment, it returned to normal, and three patients had different degrees of mass. The analysis on the three-dimensional reconstruction data and the assessments from both the physicians and patients showed significant differences in the fat graft retention volume between the BTX-A group (51.10±20.56)% and the control group (33.06±14.77)%. Nevertheless, there was no significant difference in the incidence of complications between the two sides.Conclusions:Autogenous fat breast augmentation is safe and effective. This study result has shown that BTX-A can significantly improve the retention rate of fat transplantation but cannot reduce the incidence of complications.

Tétanos y uso de toxina botulínica: reporte de caso / Tetanus and botulinum toxin use: report of a case

RESUMEN El tétanos es un trastorno del sistema nervioso caracterizado por espasmos musculares causados por las toxinas de Clostridium tetani, un bacilo anaerobio, que se encuentra en el suelo y cuyas esporas sobreviven en el ambiente y causan infección al contaminar las heridas. El objetivo de este reporte de caso es dar a conocer los aspectos básicos de esta enfermedad, hacer un enfoque en la mejoría de la funcionalidad con la aplicación de toxina botulínica tipo A para la espasticidad generalizada y el trismo. Presentamos el caso de una mujer de 81 años con tétanos generalizado y presencia de trismo con antecedente de traumatismo craneal secundario a caída desde su propia altura sin pérdida del conocimiento 15 días previos al ingreso a la institución de salud. Durante su estancia hospitalaria el tratamiento fue multidisciplinario. La paciente egresó en buenas condiciones generales con seguimiento en consulta externa.

ABSTRACT Tetanus is a condition affecting the central nervous system which is characterized by muscle spasms caused by toxins from Clostridium tetani, an anaerobe bacillus which is usually found on soil and whose spores may survive in the environment and lead to infection when contaminating open wounds. The objective of this case report is to review on the basic characteristics of this condition, focusing on functional improvement with the administration of type A botulinum toxin for generalized spasticity and lockjaw (trismus). We present the case of an 81-year-old woman with generalized tetanus and lockjaw after she suffered a head injury, she fell and hurt her head, with no loss of consciousness; and that was 15 days before admission. During her hospital stay she was managed by a multidisciplinary team. The patient did well, and she is currently being followed-up in the outpatient clinic.

Misdiagnosis of iatrogenic botulinum toxin poisoning:one case report and review of the literature / 中国基层医药

Objective To report 1 case of iatrogenic botulinum poisoning misdiagnosed as myasthenia gravis,to discuss the clinical manifestation,distinguishing feature and prognosis of iatrogenic botulinum poisoning combined with literature.Methods We briefly introduced one patient with botulinum toxin poisoning misdiagnosed as myasthenia gravis.A 26-year old female was admitted in June 2017 in Gaochun People's Hospital of Nanjing,who received two injections of botulinum toxin 500 U for a short period of time due to cosmetic needs,then she suffered from fatigue,chest distress,eyelid ptosis and other symptoms.The patient was once misdiagnosed as myasthenia gravis,but the results of neostigmine test and repeated nerve stimulation examination were negative.After careful examination of the body (mandibular swelling) and repeated medical history requiring,the final diagnosis was clarified.After the treatment such as fluid infusion for 10 days,her discomforts were relieved.The literature was retrieved from "US National Library of Medicine National Institutes of Health (Pubmed) "," China National Knowledge Infrastructure (CNKI)" and "Wanfang Medicine Data China Information",a total of 17 articles were included in the analysis,including 30 effective cases.We analyzed the general characteristics,clinical manifestations and prognosis of botulinum toxin injection.Results Of the 30 cases,28 cases (96.7％) were female,2 cases (3.0％) were male,aged from 3 to 80 years old.Most of them were botulinum toxin type A,except 2 cases unknown.The clinical onset began from the injection day to 3 weeks after injection.The duration of the disease lasted from 10 days to 6 months.Most of the prognosis was good after treatment.Conclusion Careful attention should be paid to the serious reaction of botulinum toxin to ensure safe medication use.

Evaluation of botulinum toxin A injections for the treatment of glabellar lines by using high-frequency ultrasound / 中华皮肤科杂志

Objective To investigate changes in thickness of the skin and muscular layer during the treatment with botulinum toxin A injections in patients with glabellar lines.Methods Twenty-six subjects with moderate to severe glabellar lines were enrolled into this study,who received botulinum toxin A injections in Peking Union Medical College Hospital from August 2017 to February 2018.Before the injections,4 and 16 weeks after the injections,thickness of the dermis at the injection site was measured by using 50 MHz high-frequency ultrasound,and full thickness of the skin and thickness of the muscular layer were measured with 20 MHz high-frequency ultrasound.Repeated measures analysis of variance,paired ttest and Bonferroni method were used to compare the pretreatment and posttreatment tissue thicknesses measured by using high-frequency ultrasound.Results Before the injections,the thickness of the dermis,full thickness of the skin,thickness of the muscular layer were 2.01 ± 0.48,4.32 ± 0.73 and 4.51 ± 0.67 mm respectively.No significant difference was observed among the pretreatment,4-and 16-week posttreatment thickness of the dermis (F =1.94,P =0.199),while there were significant differences among the pretreatment,4-and 16-week posttreatment full thickness of the skin and thickness of the muscular layer (F =6.28,24.19,P =0.020,＜ 0.001 respectively).Four weeks after the injections,the full thickness of the skin significantly increased (4.88 ± 0.93 mm,t =3.72,P =0.004),while the thickness of the muscular layer significantly decreased (3.82 ± 0.79 mm,t =4.65,P =0.001)compared with the pretreatment thicknesses.Sixteen weeks after the injections,the full thickness of the skin (4.61 ± 0.73 mm) and thickness of the muscular layer (4.38 ± 0.90 mm) did not significantly differ from those before and 4 weeks after the injections (all P ＞ 0.016 7).Conclusions Botulinum toxin A injections can change the thickness of the subcutaneous tissue and muscular layer.High-frequency ultrasound can be applied to the evaluation of efficacy and to follow-up after the treatment of glabellar lines with botulinum toxin A injections.

TOXINA BOTULÍNICA NA ODONTOLOGIA / THE USE OF BOTULINUM TOXIN IN DENTISTRY

A Clostridium botulinum é uma bactéria anaeróbia que produz 8 tipos de toxinas. A Toxina Botulínica tipo A (BTX-A) é a variedade mais potente e a única utilizada em procedimentos clínicos e aprovada para uso cosmético e terapêutico. A empresa Allergan Inc. (USA) foi a primeira a produzir a BTX-A com o nome comercial de "BOTOX®". No Brasil sua aplicação terapêutica foi aprovada pela ANVISA em 2000, e nos Estados Unidos da América em 2002 pela Food and Drug Administration. O Conselho Federal de Odontologia reconhece pela Resolução 198/2019 sua utilização em procedimentos de harmonização orofacial bem como em procedimentos terapêuticos. Sua aplicação em casos como bruxismo, hipertrofia dos músculos da mastigação, disfunções temporomandibulares, sialorreia, assimetria de sorriso e exposição gengival acentuada, apresenta bons resultados, muito embora temporários. As contraindicações para o uso da BTX-A são expressas principalmente para a miastenia grave e a síndrome de Lambert-Eaton, consistentes em uma desordem caracterizada pela redução da liberação da acetilcolina nas sinapses. O presente trabalho teve como objetivo revisar a literatura sobre as aplicações da Toxina Botulínica no âmbito da Odontologia, abrangendo tanto a área da estética facial quanto a resolução de problemas ligados à área odontológica. Concluiu-se que seu uso é de baixo risco e com efeito positivo evidente nos casos específicos de aplicação terapêutica, além de melhorar a estética e, por consequência, a autoestima do paciente, proporcionando-lhe conforto e bem-estar.

Clostridium botulinum is an anaerobic bacter, which produces until eight types of toxins. The botulinum toxin A (BTX-A) is the most potent among then, largely used in clinical procedures and approved for several therapeutic instances. The Allergan Inc. company was the first to produce BTX-A commercially called as "Botox®". The therapeutic use of BOTOX® is approved by ANVISA in Brazil since 2000, followed by Food and Drug Administrartion in 2002. In Brazil, the Federal Council of Dentistry recognizes BOTOX® by 198/2019 law and its utilization in procedures such as facial reconcilement; or in therapeutics such as bruxism, hypertrophy of chew muscles, temporomandibular joint dysfunction, sialorrhea, asymmetry smile, and gingival profusion. Despite its temporal use, the results are very interesting. BTX-A side effects are considered for uses in miastenia gravis and Lambert-Eaton Syndrome, which has, in common, a reduced acetylcholine release in synapses. Thus, the aim of this work was to review the main BTX-A uses in dentistry area, once its use has growing largely in aesthetics and in dentistry disorders. Herein, we report the low risk in the use of BTX-A, with several interesting benefits on dentistry areas, improving the quality of life and the self- esteem.

Harmonization of gummy smile by techniques of gingivoplasty and botulinum toxin application / Harmonização do sorriso gengival pelas técnicas de gengivoplastia e aplicação da toxina botulínica

The esthetic excellence has become the main objective in the dental treatment. The gummy smile is one of the complaints from the patients, since this situation may influence their self-esteem, social relationship and quality of life. The development of new techniques search to be therapeutic option more conservative, in the treatment of gummy smile, such as the association between the gingivoplasty and application of botulinum toxin, in comparation with other surgical procedures as the orthognatic surgery. The purpose of this article is to present a case of a patient with dentogingival discrepancy and gummy smile, who was treated with the association of these techniques, in order to optimize the harmony of the smile

A excelência estética tornou-se o principal objetivo no tratamento odontológico. O sorriso gengival é uma das queixas dos pacientes, uma vez que esta situação pode influenciar a sua autoestima, relação social e qualidade de vida. O desenvolvimento de novas técnicas busca ser uma opção terapêutica mais conservadora, no tratamento do sorriso gengival, como a associação entre a gengivoplastia e a aplicação da toxina botulínica, em comparação com outros procedimentos cirúrgicos como a cirurgia ortognática. O objetivo deste artigo é apresentar um caso de uma paciente com discrepância dentogengival e sorriso gengival, que foi tratada com a associação dessas técnicas, a fim de otimizar a harmonia do sorriso.